The move raises privacy concerns as the drugmaker takes control of the genetic data of millions of clients of the once-sizzling DNA-testing startup.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron is offering to keep all of the former company's employees.